Market Highlights:Global Light Therapy Market Research Report: By Product (Light Box, Floor and Desk Lamps, Light Visor, HDST, Others), By Application (Psoriasis, Vitiligo, Eczema, Acne Vulgaris, Others), By Light Type (Blue Light, Red Light, White Light, Others) and By End-User (Homecare Settings, Dermatology Clinics, Others) – Forecast to 2025Registering a CAGR of 5.1%, the Global Light Therapy Market is expected to reach USD 1,112.16 Million in by 2025.The increasing patient preference for non-invasive procedures is driving the growth of this market.

Various medical facilities are now preferring to use non-invasive light therapies or phototherapies.

This can be attributed to the advantages of non-invasive light therapy, such as reduced pain and better patient outcomes.Numerous established players dominate the market.

For instance, in April 2019, Philips launched VitalMinds a key technology in the personalized light therapy system, that improves sleep quality in critical care patients.Key Players:Northern Light Technology (Canada)Chal-Tec GmbH (Germany)Beurer (Germany)BioPhotas (US)Lucimed SA (Belgium)Verilux (US)Koninklijke Philips (Netherlands)Nature Bright (Taiwan)Zepter International (Switzerland)Lumie (UK)Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/8366             Segmentation:The global light therapy market has been segmented into product, application, light type, and end user.By product, the market has been segmented into light box, floor and desk lamps, light visor, handheld devices for skin treatment (HDST), dawn simulator, light therapy bulbs, and others.By application, the market has been segmented into psoriasis, vitiligo, eczema, acne vulgaris, seasonal affective disorder (SAD), and others.

The psoriasis segment is estimated to hold significant market share in the market due to the increasing prevalence of psoriasis and demand for novel therapeutics.

For instance, about 1.9 percent of African Americans have psoriasis.

Market Highlights:Feminine Hygiene Market Research Report: Information by Product Type (Sanitary Napkins/Pads, Tampons, Panty Liners, Others), Distribution Channel (Supermarket and Department Stores, Retail Pharmacies, Others) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) – Global Forecast till 2024The global feminine hygiene market was valued at USD 21.96 Billion in 2018.

The market is projected to register a CAGR of 7.2 % during the forecast period of 2019 to 2024.Numerous factors, such as the rising disposable income of the middle class in emerging countries such as Brazil and China, and the emergence of low-cost feminine hygiene products.

However, the increasing number of product recalls due to several factors such as the growing allergy cases among women and the presence of toxic chemicals in feminine products are anticipated to hinder the growth of the global feminine hygiene market.Key Players:Some of the key players in the global feminine hygiene market are Johnson & Johnson, Procter and Gamble, Edgewell Personal Care, Unicharm Corporation, Ontex International, Svenska Cellulosa Aktiebolaget SCA, Kimberly-Clark Corporation, Lil-Lets Group Ltd, Natracare LLC, and Kao Corporation.Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/7986         Segmentation:The global feminine hygiene market, based on product type, has been segmented into sanitary napkins/pads, tampons, panty liners, menstrual cups, and feminine hygiene wash.

The sanitary napkins/pads segment is anticipated to hold the largest market share as they have a high adoption rate among women across all geographic regions.

Additionally, the growing awareness about feminine hygiene products owing to several initiatives taken by the government and the non-government organization in this region is anticipated to boost the market growth.Americas is expected to hold a second market position in the global feminine hygiene market.

The market growth in the region is attributed to the high penetration of high-end products such as tampons, panty liners, and internal cleansers, an increasing number of working women, and growing demand by women for organic and biodegradable products.Europe is likely to show a significant amount of growth in the global feminine hygiene market.

Market Highlights:Global Coronary Stents Market Research Report: by Products (Drug Eluting Stents, Bare Metal Stents, and Bioresorbable Vascular Scaffolds), By End-Users (Hospitals and clinics, ambulatory surgical center, specialty center, and others) – Forecast Till 2023Global Coronary Stents Market held a market value of USD 9,382.63 million in 2017 and is projected to grow at a CAGR of 7.81% over the forecast period.Coronary stents are used in the process of angioplasty to make the cross-section of the blood vessel wider.

Coronary stents have revolutionized the practice of interventional cardiology by reducing early complications such as abrupt vessel closure and improving late clinical outcome (restenosis).

This results in patient and physician satisfaction.

Thus, this factor contributes heavily to the growth of this market.Key Players:Some of the prominent players in the global coronary stents market are Abbott, B. Braun Melsungen AG, Biotronik SE & Co. KG,        Boston Scientific Corporation, C. R. Bard, Inc., Cook Medical, Elixir Medical Corporation, Medtronic plc, Meril Life Sciences, MicroPort Scientific Corporation, Stentys SA, and Terumo Corporation.Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/6938     Segmentation:Global coronary stents market has been segmented into products, and end user.Based on products, the market has been segmented into, Drug Eluting Stents, Bare Metal Stents, and Bioresorbable Vascular Scaffolds.

This large share is majorly attributed to the wider acceptance of the drug eluting stents in the angioplasty procedures, better patient compliance as compared to the bare metal stents.

On the basis of end users, the market has been segmented into hospitals & clinics, ambulatory surgical centers, specialty centers, and others.

Market Highlights:Medical Device Reprocessing Market Segmentation by Product & Service: Reprocessed Medical Devices, Reprocessing Support and Services; Type of Medical Device: Catheters, Laparoscopy Instruments, Biopsy Instruments, Endoscopy Instruments, Cables, Columns, and Cutters; Application: General Surgery, Cardiology, Orthopedic, Gastroenterology, Urology and Regions – Global Forecast to 2025Registering a CAGR of 16.4%, the Global Medical Device Reprocessing Market is expected to reach USD 2,671.8 Million by 2025.Medical device reprocessing is gaining popularity as it allows major cost savings and reduces hospital waste.

For instance, Kaiser Permanente, a US-based integrated delivery network, saves approximately USD 11 million on an annual basis by reprocessing of medical devices.

Medical waste treatment puts lots of cost pressure on hospitals; however, in countries such as the US, Japan and China, it has become a full-fledged industry.

For instance, Ascent, a subsidiary of Stryker Corporation, eliminated 1,684 tons of medical waste with the help of reprocessing.Market Key Players:Medtronic PLC (Ireland)Stryker Corporation (US)Johnson & Johnson (US)Vanguard AG (Germany)AGITO MEDICAL A/S (Denmark)Medline Industries, Inc. (US)SteriPro (Canada)Block Imaging (US)EverX Pvt Ltd (Australia)SureTek Medical (US)ReNu Medical, Inc. (Arjo) (US)Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/8796      Segment AnalysisThe Global Medical Device Reprocessing Market has been segmented into Product & Service, Type Of Medical Device, and Application.By product & service, the market has been segregated into reprocessed medical devices and reprocessing support and services.

The reprocessing support and services are expected to hold the largest market share due to the rising preference of customers for reprocessing services by third-party reprocesses with reduced expenses and decreased environmental impact.By type of medical device, the market has been bifurcated into catheters, laparoscopy instruments, biopsy instruments, endoscopy instruments, and cables, columns, and cutters.On the basis of application, the global medical device reprocessing market has been classified as general surgery, cardiology, orthopaedic, gastroenterology, urology, and others.

The cardiology segment is expected to hold the largest market share owing to the increasing adoption of electrophysiology catheters by hospitals & clinics for various surgical procedures.Regional Analysis:On a regional basis, the Americas is anticipated to dominate the global medical device reprocessing market owing to the presence of a favorable regulatory scenario to increase the safety and efficacy of the reprocessed medical device.

Market Highlights:Healthcare Artificial Intelligence (AI) Market Research Report: Information By Component (Hardware, Software, Services), Application (Robot-Assisted Surgery, Virtual Nursing Assistant, Dosage Error Reduction, Clinical Trial, Preliminary Diagnosis, Automated Image Diagnosis), Technology (Machine Learning, Querying Method, Natural Language Processing), End User (Hospital & Diagnostic Centers, Pharmaceutical & Biotechnology Companies Academic & Research Laboratories) – Global Forecast till 2023According to MRFR, the Global Healthcare Artificial Intelligence Market is expected to register a CAGR of 51.9% and acquire a USD 12.22 Billion valuation by 2023 during the forecast period (2018 to 2023).

The rapid adoption of artificial intelligence in healthcare duplicating the retail industry is another positive sign of the market.

The explosive growth of seed and venture funding coupled with interest of giants such as Google and Microsoft has resulted in large enthusiasm for the industry.

Health IT companies were at the forefront of venture capital funding gathering a whopping USD 1.1 billion in 2016 alone!

This coupled with the attractive economics of up scaling and expanding has resulted in flurry of investments in the sector.Google, and Microsoft are data led artificial intelligence first companies with Machine learning and cloud deeply embedded in their products and strategies.

Oncology has received the greatest attention in the market regarding the diagnosis using AI.

Market Highlights:Plasma Fractionation Market Research Report: By Product (Immunoglobulin, Coagulation Factor Concentrates, Albumin, Protease Inhibitors, and Others), Application (Immunology, Neurology, Hematology, and Others), End User – Global Forecast Till 2023The global plasma fractionation market is expected to grow at an approximate CAGR of 6.5% during forecast period, 2018–2023.Rising participation of market players is one of the key factors driving the plasma fractionation market.

For instance, in 2018, Grifols acquired 24 plasma donation centers in the United States operated by Biotest Pharmaceuticals Corp. for USD 286 million.

With this acquisition, Grifols now owns 249 plasma donation centres to increase its supply of plasma proteins used for therapeutic purposes.Various other factors such as increasing geriatric population, technological advancements, emerging markets in APAC and RoW, rising plasma collection, and increasing prevalence of respiratory and autoimmune disorders are also expected to propel the growth of the market.However, the emergence of recombinant alternatives, high cost of advanced products, and unfavorable reimbursement policies can hamper the market growth over the forecast period.Key Players:Some of the key players in the global plasma fractionation market:-Bio Products Laboratory (BPL), Biotest AG, China Biologic Products Holdings, Inc., CSL Limited, Green Cross Corporation, Grifols, S.A., Japan Blood Products Organization, Kedrion S.p.A, LFB group, Octapharma AG, Sanquin, Shanghai RAAS, Shire, and others.Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/7397        Segmentation:The global plasma fractionation market is segmented based on product, application, end user, and region.The global market for plasma fractionation, by product is segmented into immunoglobulin, coagulation factor concentrates, albumin, protease inhibitors, and others.

The coagulation factor concentrates segment is further classified as Factor VIII, Factor IX, Von Willebrand Factor, Prothrombin Complex Concentrate, Fibrinogen Concentrates, and Factor XIII.Based on application, the market is segmented into immunology, neurology, hematology, critical care, pulmonology, rheumatology, hemato-oncology, and others.Based on end user, the market is segmented into hospitals & clinics, clinical research laboratories, academic institutes, and othersRegional Analysis:The Americas dominated the global market for plasma fractionation owing to the presence of major market players and increasing prevalence of immunodeficiency disorders within the region.

According to the 2018 study published in the Allergy, Asthma & Clinical Immunology journal, the estimated overall prevalence of immunoglobulin A (IgA) deficiency in the US was approximately 1 in 300 to 1 in 500 persons.In 2017, it was estimated that Europe stood second in the global plasma fractionation market.

This can be attributed to the increasing technological advancements, and rising R investments.Asia Pacific was projected to be the fastest growing region in 2017.

Market Highlights:Global High Potency APIs (HPAPI) Market Research Report: By Product (Biotech, Synthetic), By Type (Novel, Innovative, Generic) and By Therapeutic Area (Oncology, Glaucoma, Hormonal) – Forecast to 2025.According to the latest analysis published by Market Research Future (MRFR), the global high potency APIs market is set to strike a CAGR of 8.40% during the forecast period 2018 to 2023.

Thus, the rising prevalence of chronic and old age diseases have intensified the demand for HPAPIs.The rapid expansion of cancer patient pool is forecasted to accelerate the revenue creation for the market players globally.

The competitive landscape of the market is highly lucrative and rising investments is prognosticated to boost the manufacturing of HPAPIs.

Furthermore, the key players are anticipated to strategize agreements, acquisitions, and partnerships for gaining edge over competitors.The developments witnessed in the healthcare sectors of the fast-developing economies such as China, India, and Japan are forecasted to revolutionize the HPAPI market in the foreseeable future.

Nevertheless, lack of global regulatory framework is expected to hold the expansion of the market across the projection period.Global Market for High Potency APIs – Competitive Dashboard:Some of the key players profiled in the report are Teva Pharmaceuticals, SAFC, Carbogen Amics, Bristol-Myers Squibb, Asymchem, Lonza, Bayer AG, Boehringer Ingelheim, and Sanofi.Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/6679    Global High Potency APIs Market – Segmental Analysis:This MRFR’s report offers a detailed segmental analysis of the global high potency APIs market based on product, type and therapeutic area.

The rising demand for antibody-drug conjugates (ADCs) is expected to propel the expansion of the biotech segment in the foreseeable future.By type, the market has been segmented into novel or innovative, and generic.

Market Highlights:Wearable Ambulatory Monitoring Devices Market: Information by Product Type (Cardiac Event Monitors, Holter Monitor, Mobile Cardiac Telemetry Devices) and Region (Americas, Europe, Asia-Pacific, Middle East & Africa) – Global Forecast till 2025Global Wearable Ambulatory Monitoring Devices Market is expected to register a CAGR of 6.48% during the forecast period with a market value of USD 4,990.8 Million till 2025.

Wearable ambulatory monitoring devices are portable electrocardiograph machines attached either to patients’ body or inserted below the skin.

Each type of monitor has differentiated in terms of length of heart rhythm recording time.Market Key Players:MRFR recognizes the following companies as the Key Players in the Global Wearable Ambulatory Monitoring Devices Market— General Electric Company (US), ACS Diagnostics (US), BioTelemetry (US), iRhythm Technologies, Inc. (US), Medicomp Inc. (US), Medtronic PLC (Europe), Preventice Solutions, Inc. (US), Telerhythmics, LLC (US), Hill-Rom Services Inc. (US), and ZOLL Medical Corporation (US).Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/8740     Segment AnalysisThe Global Wearable Ambulatory Monitoring Devices Market has been segmented by product type.

Based on product type, wearable ambulatory monitoring devices market has been segregated into cardiac event monitors, Holter monitor, mobile cardiac telemetry devices, and others.Regional Analysis:The Global Wearable Ambulatory Monitoring Devices Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.The Americas are likely to dominate the global wearable ambulatory monitoring devices market.

This can be attributed to the high prevalence of cardiovascular diseases in the region.

According to the American Heart Association (AHA), in 2015, an estimated 4 million Americans suffered from recurrent arrhythmias.

Market Highlights:AR & VR in Healthcare Market Research Report: By Technology (AR and VR technology), Offering (Hardware & Software), Device Type (AR & VR Device Type), Application (Fitness, Patient Care, Pharmacy Management & Others), End User – Global Forecast Till 2023The AR & VR in healthcare market is expected to grow at an approximate CAGR of 30.2% during forecast period, 2018–2023.Rising demand to reduce healthcare cost is one of the key factors driving the AR & VR in healthcare market.

For instance, with the use of AR navigation system nearly USD 288 million can be saved on minimally-invasive surgical procedures in the US.Various other factors such as rising government funding, high prevalence of chronic diseases, rising adoption of AR and VR in fitness management, increasing penetration of connected devices in the healthcare sector, and rising awareness about VR therapy are also expected to propel the growth of the market.However, concerns regarding data privacy, lack of expertise among medical practitioners, and lack of competence in deployment of the AR and VR solutions can hinder the market growth over the forecast period.Key Players:Some of the key players in the AR & VR in healthcare market are Atheer, Augmedix, Daqri, Firsthand Technology, Google, Medical Realities, Microsoft, Mindmaze, Oculus VR, Psious, EchoPixel, Inc., Osso VR Inc., SURGICAL THEATER, LLC, Orca Health, Inc., Hologic Inc., 3D Systems, Inc., and others.Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/7208           Segmentation:The AR & VR in healthcare market is segmented based on technology, offering, device type, application, end user, and region.The global market for AR & VR in healthcare, by technology is segmented into AR technology and VR technology.

The AR technology segment is further classified as marker-based AR and markerless AR.

The sensors segment includes accelerometer, gyroscope, magnetometer, and proximity sensor.

The software segment is further classified as software development kits, and cloud-based services.Based on device type, the market is segmented into AR device type, and VR device type.

The AR device type segment is further classified as head-mounted display, and handheld device.

Market Highlights:Global Blood Collection Market Research Report: by Type of blood collection (capillary, venous, vacuum), by product (blood collection devices, blood collection tubes, needles and syringes, lancets), by method (automated, manual), end user – Forecast Till 2023The Global Blood Collection Market is expected to grow at a CAGR of 6.1% during the forecast period.

Increasing prevalence of chronic conditions, advancements in healthcare facilities, and favorable funding policies are expected to drive the market growth over the forecast period.

According to the World Health Organization (WHO), there are over 35 Million healthcare workers and these workers face an increased risk of infection from blood-borne pathogens simply because of their exposure to blood and other body fluids.

However, blood contamination and injury caused by blood collection devices can restrain the market growth over the assessment period.Key Players:Some of the prominent players in the global blood collection market-BD, Medtronic, Terumo, Haemonetics, Fresenius, Nipro Medical, Kawasumi Laboratories, F.L.

Medical, Greiner Holding, Grifols, B. Braun Melsungen AG, Thermo Fisher Scientific Inc., HTL-STREFA S.A., Sarstedt AG & Co and others.Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/7013       Segmentation:The Global Blood Collection Market has been segmented into type of blood collection, product, method, and end user.The market, on the basis of type of blood collection, has been segmented into capillary blood collection, venous blood collection, and vacuum blood collection.The market, by product, has been segmented into blood collection devices, blood collection tubes and collector, needles and syringes, warming devices, blood bags, lancets, and others.

The blood collection tubes and collector segment is further classified as serum collection tubes, and plasma or whole blood collection tubes.

Market Highlights:Global COVID-19 Diagnostics Market: Information by Type (Molecular Tests, Serology Tests), Technology (RT-PCR, Isothermal Amplification, CRISPR, ELISA, Hybridization), End-User (Hospitals, Public Health Labs, Private or Commercial Labs) and Region (Americas, Europe, Asia-Pacific, Middle East & Africa) – Forecast till 2027Global COVID-19 Diagnostics Market is expected to register a CAGR of 6.28% during the forecast period, with a market value of USD 96,293.9 Million by 2027.

COVID-19 is one of the most harmful infectious diseases that is caused by a coronavirus.

Wuhan, China was the first place to experience the disease’s outbreak, followed by Europe, and then to the other countries globally by infected people.MRFR recognizes the following companies as the Key Players in the Global COVID-19 Diagnostics Market— Becton, Dickinson & Company (US), Bio-Rad Laboratories (US), Danaher Corporation (US), Abbott (US), F. Hoffmann-La Roche Ltd (Switzerland), Biomerieux SA (France), Genmark Diagnostics (US), Thermo Fisher Scientific (US), Qiagen (Germany), and Siemens AG (Germany).Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/9710        Segment AnalysisGlobal COVID-19 Diagnostics Market has been segmented by Type, Technology, and End Users.

The market, based on type, has been bifurcated into molecular tests and serology tests.

On the basis of technology, the market has been bifurcated into RT-PCR, isothermal amplification, CRISPR, ELISA, hybridization, and others.Based on End User, the COVID-19 diagnostics market has been segregated into hospitals, public health labs, private or commercial labs, and others.Regional Analysis:Global COVID-19 Diagnostics Market, based on region, has been divided into the Europe, Americas, Asia-Pacific, and the Middle East & Africa.The Europe is likely to dominate the global COVID-19 diagnostics market.

This can be attributed to the high COVID-19 morbidity and mortality observed among residents in long-term care facilities (LTCF) in European Union (EU) and European Economic Area (EEA) pose a major challenge for disease prevention and control in such settings, which raises the demand for the wide availability of diagnostics for immediate detection of COVID-19 cases.

Market Highlights:Global H. Pylori (Helicobacter Pylori) Test Market Research Report: By Test Type (Non-Endoscopic, Endoscopic), By Technology (Immunoassays, Point-of-Care (POC), Molecular Diagnostics) and By End-User (Hospitals and Clinics, Diagnostics Laboratories, Others) – Forecast to 2025According to MRFR analysis, H. Pylori (Helicobacter Pylori) Test Market is expected to register a CAGR of 5.2% during the forecast period of 2019 to 2025 and is expected to reach USD 2,924.2 Million by 2025.

On the contrary, low diagnosis rates of helicobacter pylori infection in developing nations is anticipated to limit the market growth during the review period.Market Key Players:Some of the key players in the Global H. Pylori Test Market are Thermo Fisher Scientific Inc. (US), Bio-Rad Laboratories, Inc. (US), Quest Diagnostics Incorporated (US), F. Hoffmann-La Roche Ltd (Switzerland), Meridian Bioscience (US), CorisBioconcept SPRL (Belgium), Cardinal Health (US), Abbott Laboratories (US), QIAGEN (Germany), and Biohit Oyj (Finland).Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/8497    Segment AnalysisThe Global H. Pylori Test Market has been segmented based on test type, technology, and end-user.Based on the test type, the market has been divided into non-endoscopic and endoscopic.

The non-endoscopic segment has been further classified as stool/fecal antigen test (SAT), urea breath test (UBT), and serology/antibody/blood test.

The endoscopic segment is additionally categorized into culture, histology, rapid urease/campylobacter-like organism (CLO) test, and polymerase chain reaction (PCR).

Molecular methods are widely used for the diagnosis of H. pylori and to analyze diversity, virulence, and resistance patterns of these bacteria.

This has contributed to the segment’s second-largest position in 2018.By end-user, the market has been bifurcated into hospitals and clinics, diagnostics laboratories, and others.

Market Highlights:Global CAR T Cell Therapy Market: Information By Target Antigen (CD19, CD22), By Application (Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia) and Region (US, Europe, China and Rest of World) – Forecast till 2027Global CAR T Cell Therapy Market is expected to register a CAGR of 42.98% during the assessment period of 2020 to 2027, to reach USD 10,415.61 Million by 2027.In this type of treatment, ‘the patient’s T cells are transformed in the laboratory to work against cancer cells.

Large numbers of CAR T cells are developed in the laboratory and transmitted into the patient by infusion.

Technological advancements in the treatment therapies for cancer is anticipated to further drive the demand for CAR T cell therapy.Key Players:MRFR recognizes the following companies as the Key Players in the Global CAR T Cell Therapy Market— Pfizer (US), Kite Pharma (US), Novartis (Switzerland), Cellectis (Switzerland), and Juno Therapeutics (US).Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/8102          Segmentation:The global CAR T cell therapy market is segmented based on the target antigen and application.

On the basis of application, the market is bifurcated into diffuse large B-cell lymphoma, acute lymphoblastic leukemia, and others.Regional Analysis:Global CAR T Cell Therapy Market, based on region, has been divided into the US, Europe, China, and the Rest of the World.The US dominated the market in 2019 and is likely to continue to command during the assessment period.

Furthermore, in the US, there were an estimated 1,762,450 new cancer cases diagnosed and 606,880 deaths due to cancer in 2019.

According to the statistics published by Cancer Research UK, incidence rates for all cancers are projected to rise by 2% in the UK between 2014 and 2035 to 742 cases per 100,000 people by 2035.

Market Highlights:Global Corporate Wellness Market Research Report: by Service Type (Health Risk Assessment, Stress Management, Nutrition & Weight Management, Smoking Cessation, Fitness), Category (Fitness & Nutrition Consultant, Organization), End User- Forecast Till 2023The Global Corporate Wellness Market held a market value of USD 49.7 billion in 2017 and is projected to grow at a CAGR of 7.0% over the forecast period.

Corporate wellness programs are health promotion activities designed & conducted by corporate employers to support employees to understand their health risks, pursue healthy behavior at the workplace, and decrease the expenditure on healthcare.

Currently, these programs are increasingly conducted by corporates in order to increase the productivity, decrease absenteeism, and improve morale & quality of work of their employees.

An employee works almost 9 hours in corporate offices and during this period, most of the employees sit continuously and are physically inactive.

Few of the major market growth factors include globally growing geriatric population coupled with increasing prevalence of chronic diseases, increasing private sector capital expenditure, a surge in the number of service sector employees, and rising financial burden of insurance costs on employers.

For instance, the Centers for Disease Control and Prevention (CDC) reported that, in the US, 6 in 10 adults have a chronic disease and 4 in 10 adults have two or more chronic diseases such as stroke, diabetes, heart disease, cancer, chronic lung disease, and chronic kidney disease (CKD).Key Players:Some of the prominent players in the global corporate wellness market are Wellness Corporate Solutions, LLC, ComPsych Corporation, Wellsource, Inc., SOL Wellness, Central Corporate Wellness, Truworth Health Technologies Pvt.

Market Highlights:Global Biomarkers Market: Information By Product (Consumables, Services, Software), By Type (Safety Biomarkers, Validation Biomarkers, Efficacy Biomarkers), By Application (Diagnostics, Personalized Medicine, Drug Discovery and Development, Disease Risk Assessment) and By Disease Indication (Cancer, Neurological Disorders, Cardiovascular Disorders, Immunological Disorders, Others) – Forecast till 2027Global Biomarkers Market is expected to have a market value of USD 64,265.19 Million by 2027.

The global biomarkers market, by application, has been segmented into diagnostics, drug discovery and development, personalized medicine, disease risk assessment, and others.The global biomarkers market, by disease indication, has been segmented into cancer, cardiovascular disorders, neurological disorders, immunological disorders, and others.

The presence of prominent biopharmaceutical companies such as Merck Millipore, Bio-Rad Laboratories, Inc., Illumina, Inc., and Agilent Technologies in the US, facilitates early market initiation and prompt supply chain management.

Players headquartered in other regions are also actively involved in the expansion of their facilities in the American countries to capture maximum share in the region.The European biomarkers market has been further segmented into Western Europe and Eastern Europe.

The Western Europe biomarkers market has further been classified into Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

For instance, European Cancer Patient Coalition (ECPC), an organization representing more than 447 organization in 46 EU and non-EU countries, in partnership with Cancer Drug Development Forum (CDDF), European Alliance for Personalized Medicine (EAPM), and International Quality Network for Pathology (IQN-Path), launched the first-ever Personalized Medicine Awareness Month in November 2018.

Market Highlights:Global HbA1c Testing  Market: Information by Product (Instruments (Bench-Top Device and Handheld Device) and Reagents and Kits), By Technology (Ion-Exchange High-Performance Liquid Chromatography (HPLC), Turbidimetric Inhibition Immunoassay (TINIA), Enzymatic Assay and Others), By End User (Hospitals and Clinics, Diagnostic Laboratories and Others) and by Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) – Forecast till 2025HbA1c Testing Market is expected to register a CAGR of 12.24% during the forecast period, with a market value of USD 1,992.44 Million till 2025.

HbA1c tests measure the blood glucose levels only for the past six to eight weeks.

Hemoglobin is the oxygen-carrying pigment that gives the blood its red color and is also the predominant protein in red blood cells.Market Key Players:MRFR recognizes the following companies as the key players in the Global HbA1c Testing Market—Abbott Laboratories (US), ARKRAY, Inc. (Japan), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), EKF Diagnostics (UK), Danaher Corporation (US), Rapid Diagnostics Group of Companies (India), Tosoh India Pvt.

Ltd. (India), DiaSys Diagnostic Systems GmbH (Germany), Transasia Bio-Medicals (India), PTS Diagnostics (US), Agappe Diagnostics Ltd (India),  Siemens Healthineers (US), CPC Diagnostics Pvt.

Ltd. (India), and Trinity Biotech PLC (Ireland).Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/8517   Segment AnalysisThe Global HbA1c Testing Market has been segmented by product, technology, and end-user.The market, based on product, has been bifurcated into reagents and kits, and instruments.

The market, based on instruments, has been further segmented into a bench-top device and handheld device.